Phoenix Children’s Hospital is the First in Arizona to Offer New FDA Approved Epilepsy Treatment by LivaNova

Register to receive a free US Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices Market Report synopsis and brochure

Barrow Neurological Institute at Phoenix Children’s, a U.S. News and World Report “Best Children’s Hospital,” recently announced it is the first Arizona hospital to offer a new treatment for patients with drug-resistant epilepsy. The latest Vagus Nerve Stimulation Therapy® (“VNS Therapy”) System through LivaNova PLC features the recently FDA-approved SenTiva™ implantable generator, the smallest and lightest responsive therapy for epilepsy. The programming system features a wireless wand and interface on a small tablet. Together, the components offer patients with drug-resistant epilepsy a physician-directed customizable therapy with smart technology and proven results to reduce the number of seizures, lessen the duration of seizures and enable a faster recovery.

“The SenTiva from LivaNova represents the next step in caring for children with epilepsy,” said P. David Adelson, MD, Director of Barrow Neurological Institute at Phoenix Children’s Hospital, Chief of Pediatric Neurosurgery at Phoenix Children’s Hospital. “It provides Phoenix Children’s clinicians the data necessary to individualize our patients care and target their unique seizure profile.”

Phoenix Children’s is proud to offer the first epilepsy device of its size to include detect-and-respond mode, designed to prevent seizures before they start by automatically delivering extra therapy and to stop them if they do occur. SenTiva also collects and logs events commonly associated with seizures, including a patient’s body position and heart rate variations to assist physicians with developing a personalized approach to epilepsy care.

“This next generation of neuromodulation therapy allows for much more precise monitoring of when patients are having seizures and may also allow for the identification of patients at higher risk for sudden unexpected death in epilepsy,” said Angus Wilfong, MD, Associate Director of Barrow Neurological Institute at Phoenix Children’s Hospital and Chief of Pediatric Neurology at Phoenix Children’s.

The VNS Therapy Programming System provides several advanced options and personalized features, including day and night programming. For more information about the therapy, visit:

For Further Information
More on the neurology market in the United States can be found in our report published by iData entitled U.S. Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices Market, which covers market segments for Cerebrospinal Fluid Management, Intracranial Pressure Monitoring Devices, Detachable Coils, Liquid Embolics, Neurovascular Catheters, Neurovascular Guidewires, Neurovascular Stents, Neuromodulation Devices, Neuroendoscopes, Stereotactics, Ultrasonic Aspirators, Aneurysm Clips, Intrathecal Pumps, and Neurosurgery Robotic Assisted Surgery Systems.

The iData series on the market for neurology devices covers the United States, China, India, Japan and 15 Countries in Europe. Full reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. Register online or email us at for an U.S. Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices Market brochure and synopsis.

Leave a Reply